The first medical suite for preventive and personalised medicine
Fighting Age Associated Diseases before they happen
At Ambr, our goal is to research algorithmics combined with multi-omics to better understand how we age, and how diseases develop. We are dedicated to embed our research in medical software, directed toward hospital use, to support the development of preventive and personalised medicine.
Agespan, our flagship product, is a state-of-the-art medical platform suite that leverages the latest advancements in genomics, epigenetic, inflammation, and Artificial Intelligence.
Designed for healthcare professionals, Agespan offers precise disease risk predictions, personalized health recommendations, and tailored treatment insights. By analysing omics data, lifestyle factors, and medical history, Agespan empowers physicians to offer individualized care that can lead to early disease prevention and improved patient outcomes.
Our solutions
Agespan
A modular platform for preventive and personalized medicine to obtain in-depth data insights from your patient, understand risks factors, and simulate health strategies (lifestyle intervention, treatments) in record time.
Engage
An Agespan module providing a risk index for surgeons to estimate post-operative complications, and develop personalized prehabilitation programs to maximise recovery (In collaboration with Bærum hospital and Tampere University.
NEC-AID
Support oncologist and surgeons to diagnose Neuroendocrine carcinoma and stratify tumours, repurpose treatments, discover potential targets, and identify ongoing relevant clinical trials (in collaboration with Bergen University and Haukeland Hospital).
What is the Ambr Institute?
The Ambr Institute is developing medical software solutions that harness the power of multi-omics data and explainable Artificial Intelligence (xAI) algorithms to transform personalized and preventive medicine. At its core, Ambr’s technology leverages advanced data analytics techniques to analyze diverse biological data types, including genomics, proteomics, metabolomics, and epigenomics combined with environmental factors. By integrating and interpreting these multi-omics data sets, Ambr’s software provides comprehensive insights into individual biological processes, disease susceptibility, and treatment response.
The primary focus of Ambr is to enable precise risk stratification for age-associated diseases, rare cancers, and surgical outcomes. Our software generates predictive models that accurately assess an individual’s risk of developing various age-related conditions.
In addition to disease risk prediction, Ambr’s technology also encompasses a surgical decision support module designed to optimize patient outcomes before, during, and after surgery. By analyzing patient-specific data, including preoperative health status, comorbidities, and biomarker signatures, the software assists clinicians in evaluating surgical risks, developing personalized prehabilitation plans, and predicting postoperative complications. This comprehensive approach aims to enhance patient safety, improve surgical outcomes, and streamline clinical decision-making in the perioperative setting.
Ambr’s commitment to scientific rigor and innovation drives ongoing research and development efforts to continually refine and expand its technology platform. Through collaborative partnerships with leading research institutions and healthcare providers, we remain at the forefront of advancing personalized medicine and shaping the future of healthcare delivery.
Our values
At Ambr, our work is motivated by a commitment to improving healthcare through the power of data and technology. We are driven by the belief that everyone deserves access to personalized and preventive healthcare solutions that can lead to healthier, longer lives. Our dedication extends beyond developing innovative products; we are passionate about contributing to the broader healthcare community by addressing the growing challenges of age-related diseases.
One cause we are particularly passionate about is improving access to high-quality healthcare for underserved populations. We believe that advances in medical technology should benefit everyone, not just a privileged few. By making our tools and insights more accessible, we aim to reduce health disparities and ensure that preventive care reaches those who need it most. This commitment to social responsibility reflects our core belief in the importance of equity in healthcare.
Team
Valentin A. Normand
CEO/CSO
PhD Neuroscience
Valentin did his PhD in Neuroscience at the Kavli Institute for System Neuroscience and conducted research in the Moser Lab. He has a strong background both in biology and mathematical modeling. He is responsible for steering the company’s overall strategy, day-to-day operations, and scientific direction.
Irantzu Anzar
Head of R&D
PhD in Bioinformatics
Irantzu holds a PhD degree in bioinformatic from University of Oslo. Irantzu has a strong background in personalized immunotherapy and more than 9 years of commercial experience developing bioinformatic pipelines for NGS data analysis. She is behind our bioinformatics core, curating the data required for AI models
Alise D. Midtfjord
AI Team Lead
PhD AI / Machine Learning
With a PhD in Trustworthy AI and a background in medical physics, Alise is behind the AI rending our predictions possible. She is developing innovative algorithms to predict risks of complexe diseases by integrating multi-omics data together, with a special focus on uncertainty and explainability.
Severin Elvatun
Sr. AI Scientist
PhD Machine Learning
During his PhD, Severin worked on developing data-driven algorithms for personalized cancer risk prediction. Later, he transitioned into biomedical applications of Generative AI and Federated Learning. His expertise includes data analytics, AI engineering and software development.
David Volent Lindberg
Chief Technology officer
PhD Statistics / Mathematics
David did his PhD in Statistics at NTNU. He is the former AI lead in the research department of DNV GL, and a Senior AI consultant. David focuses on data security, platform development and quality statistics associated with our predictions, along leading other data scientists and software developers.
Aslak Hougen
Chief Commercial Officer
Aslak brings extensive experience from VP Sales and CEO in companies such as Lux International, Dale Carnegie and Biztech International. He has navigated multiple industries, contributing to both start-ups and international enterprises. Aslak is responsible for our commercial activities, driving business growth and market expansion.
Chiara Dalla Santa
PhD Candidate
Chiara has a MSc in Bioinformatics from Uppsala University in Sweden, and a background in Biotechnology from the University of Trieste, Italy. Chiara has experience in machine learning & data science and a fascination for software development and medical innovation.
Maria Schüller
Quality Assurance Engineer
PhD in Pharmaceutical Chemistry
Maria earned her PhD from the Pharmacy department at the University of Oslo. She has expertise in patient safety, quality assurance, and quality management systems. Maria is responsible for overseeing the proper development of our products, supervising clinical trials, and obtaining the necessary certifications.
Board
Our advisors
Contact us
